Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Abcam

Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation

Jonathan Milner issues Open Letter to shareholders of Abcam plc

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share.

Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share

Veralto Corp

Veralto Corporation, the former Environmental & Applied Solutions segment of Danaher Corporation, has started trading as a publicly traded entity. Veralto is a $5 billion business focused on water and product quality, with 60% of sales generated from water quality services. The spinoff has resulted in Veralto commanding a premium valuation, although marking an interesting business to keep track of.

Veralto: Thoughts On The Danaher Spinoff

Danaher's revenues declined in the second quarter. Its spinoff, Veralto, began trading on Monday.

Why Shares of Danaher Are Down Monday

Danaher Corporation will complete the spin-off of its Environmental & Applied Solutions business, which will be called Veralto. Veralto is divided into two segments: Water Quality and Product Quality & Innovation, with a focus on safe drinking water and environmentally-friendly packaging. Veralto will use a derivative of Danaher's value creation framework and prioritize M&A for growth, but debt and lower credit rating may pose challenges.

Should Danaher Investors Sell New Veralto Shares?

WASHINGTON , Sept. 30, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has completed the separation of its Environmental & Applied Solutions segment, through the spin-off of Veralto Corporation.

Danaher Corporation Completes Separation of Veralto Corporation

Aramark

American Vanguard

DXC Technology

Kellogg

Kohl's

WK Kellogg Co

Vestis Corp

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices

Veralto Set to Join S&P 500; Vestis to Join S&P MidCap 400; Others to Join S&P SmallCap 600

Ebix

Danaher Corp. DHR, -0.10% spinoff Veralto Corp. VLTO.WI, +5.02% will be added to the S&P 500 before trading Monday, when it replaces DXC Technology Co. DXC, +0.59%, which in turn will move to the S&P SmallCap 600 prior to Tuesday trading. DXC Technologies will replace Ebix Inc. EBIX, -2.48% in the S&P SmallCap 600, also effective before trading Tuesday.

Veralto stock to join S&P 500, Kohl's to join S&P SmallCap 600

WASHINGTON, Sept. 26, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2023 on Tuesday, October 24, 2023 beginning at 8:00 a.m.

Danaher Schedules Third Quarter 2023 Earnings Conference Call

Popular novelist and YouTuber John Green as well as international health nonprofits had been running a weeklong pressure campaign against the company.

Danaher Lowers Price Of Tuberculosis Test After Pressure Campaign

New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent. Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost

LOS ANGELES, CA / ACCESSWIRE / September 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to r eplace Board

Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board

NEW YORK , Sept. 14, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR) of a class action securities lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Danaher Corporation(DHR) Investors of a Class Action Lawsuit and Upcoming Deadline

Advanced Micro Devices

Amplify Energy Corp.

Berry Global Group

Intuit

SK Telecom Co., Ltd.

SharkNinja Inc

September — widely regarded as the “worst month for the stock market” — is living up to its reputation. In fact, the S&P 500 is down 1% since August, in line with its average 1.1% monthly decline since 1928.

The 7 Most Undervalued Safe Stocks to Buy in September 2023

NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR), and certain officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Danaher Corporation of Class Action Lawsuit and Upcoming Deadline - DHR

Humana

Medtronic

Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.

The 3 Most Undervalued Healthcare Stocks to Buy in September 2023

NEW YORK , Sept. 12, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline.

DHR FINAL DEADLINE NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Danaher Corporation Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action - DHR

NEW YORK , Sept. 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Danaher Corporation.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Danaher Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 15, 2023 - (NYSE: DHR)

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Danaher Corporation (NYSE:DHR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/danaher-lawsuit-submission-form?prid=47636&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Danaher Corporation (DHR) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / If you suffered a loss on your Danaher Corporation (NYSE:DHR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/danaher-lawsuit-submission-form?prid=47610&wire=1 or contact Joseph E. Levi, Esq.

SHAREHOLDER ALERT: Potential Recovery for Danaher Corporation (DHR) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit

NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Attention Danaher Corporation ("Danaher") (NYSE: DHR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 21, 2022 and April 24, 2023.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Danaher Investors of a Lead Plaintiff Deadline of September 15, 2023

LOS ANGELES, CA / ACCESSWIRE / September 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

Abbott Labs

Bristol-Myers

The pharmaceutical sector will always be a sector in constant evolution and growth. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us.

The 3 Best Pharma Stocks to Buy Now: September 2023

NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR) of a class action securities lawsuit.

News for Danaher Stock (DHR)